{"created":"2023-05-15T14:59:39.748364+00:00","id":80952,"links":{},"metadata":{"_buckets":{"deposit":"2c368c4a-d622-499c-b6a0-8fd78b72196f"},"_deposit":{"created_by":1,"id":"80952","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"80952"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00080952","sets":["10:29"]},"author_link":["900480","900481","900482","900483"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2020-10-01","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Liver is a common metastatic site of gastric cancer and patients with liver metastasis of gastric cancer (LMGC) has miserable prognosis. HER2 is a therapeutic target for GC that overexpressed in 7-34% of LMGC and trastuzumab has been clinically used for the therapy of HER2 overexpressed GC. Alpha-radioimmunotherapy (α-RIT) is expected to be a promising therapeutic option for metastasis with the combination of cancer specific drug delivery of antibody and high cell cytotoxicity of α-particle. Astatine 211 (At-211) an attractive α-particle emitter with appropriate half-life and producible with cyclotron.\nWe have investigated the therapeutic efficacy and toxicity of α-RIT against LMGC using [At-211]-trastuzumab to preclinical mice model. A single treatment of α-RIT effectively eradicated LMGC without recurrence in 6/8 mice and significantly prolonged the survival compared to control. There was no severe toxicity observed as long as we monitored the bodyweight, white blood cells, biochemical test of liver and kidney function, and histological analysis of normal liver. ","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第７９回日本癌学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"李, 惠子"}],"nameIdentifiers":[{"nameIdentifier":"900480","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川, 純崇"}],"nameIdentifiers":[{"nameIdentifier":"900481","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Li, Huizi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"900482","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hasegawa, Sumitaka","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"900483","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"HER2高発現胃がん肝転移に対するα線放射免疫療法","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"HER2高発現胃がん肝転移に対するα線放射免疫療法"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-11-13"},"publish_date":"2020-11-13","publish_status":"0","recid":"80952","relation_version_is_last":true,"title":["HER2高発現胃がん肝転移に対するα線放射免疫療法"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:18:19.746098+00:00"}